Royal Bank Of Canada Alpine Immune Sciences, Inc. Transaction History

Royal Bank Of Canada

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.75 - $41.6 $151,460 - $354,972	-8,533 Reduced 84.12%	1,611 $63,000
Q4 2023 Feb 14, 2024	BUY	$8.54 - $20.22 $32,631 - $77,260	3,821 Added 60.43%	10,144 $193,000
Q3 2023 Nov 14, 2023	BUY	$10.13 - $13.98 $37,288 - $51,460	3,681 Added 139.33%	6,323 $72,000
Q2 2023 Aug 14, 2023	BUY	$6.84 - $11.91 $8,994 - $15,661	1,315 Added 99.1%	2,642 $27,000
Q1 2023 May 15, 2023	SELL	$7.0 - $8.75 $12,796 - $15,995	-1,828 Reduced 57.94%	1,327 $10,000
Q4 2022 Feb 14, 2023	BUY	$5.45 - $7.35 $16,159 - $21,792	2,965 Added 1560.53%	3,155 $23,000
Q3 2022 Nov 14, 2022	BUY	$6.89 - $9.39 $702 - $957	102 Added 115.91%	190 $1,000
Q2 2022 Aug 15, 2022	SELL	$6.71 - $9.52 $4,193 - $5,950	-625 Reduced 87.66%	88 $1,000
Q1 2022 May 16, 2022	SELL	$6.41 - $13.89 $12,172 - $26,377	-1,899 Reduced 72.7%	713 $6,000
Q4 2021 Feb 14, 2022	BUY	$10.41 - $13.95 $14,875 - $19,934	1,429 Added 120.79%	2,612 $36,000
Q3 2021 Nov 15, 2021	BUY	$8.19 - $11.31 $3,177 - $4,388	388 Added 48.81%	1,183 $12,000
Q2 2021 Aug 16, 2021	BUY	$8.81 - $15.03 $7,003 - $11,948	795 New	795 $7,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.